(Sharecast News) - Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens of its chronic lymphocytic leukaemia candidate Calquence in a first-line setting.
AstraZeneca noted that the approval of Calquence, in combination with venetoclax, follows the positive opinion of the Committee for Medicinal...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE